Boston Scientific stock falls after FDA discloses defibrillation lead issue

Published 06/08/2025, 16:02
© Reuters.

Investing.com -- Boston Scientific (NYSE:BSX) stock fell 1.8% after the U.S. Food and Drug Administration (FDA) disclosed a potentially high-risk issue with the company’s defibrillation leads that has been linked to patient deaths.

The FDA announced it is aware that Boston Scientific has notified customers about certain ENDOTAK RELIANCE Defibrillation leads with expanded polytetrafluoroethylene (ePTFE) coated coils that may impact shock efficacy and/or require early replacement. The communication is part of the FDA’s Communications Pilot to Enhance the Medical (TASE:BLWV) Device Recall Program.

According to the FDA notice, Boston Scientific has reported 386 serious injuries and 16 patient deaths associated with this issue as of July 24. The most common harm is early lead replacement, while the most serious harm is death or need for cardiac resuscitation due to non-conversion of a sustained ventricular arrhythmia from reduced shock energy due to high impedance.

The issue affects multiple models of ENDOTAK RELIANCE, RELIANCE 4-SITE, and RELIANCE 4-FRONT defibrillation leads. Boston Scientific has sent letters to healthcare providers recommending continued routine follow-up of defibrillation systems with ePTFE leads either via in-person or remote monitoring.

The company’s investigation found that calcification of the shock coil(s) does not compromise the physical or electrical integrity of the lead, but a trend of gradually rising low-voltage shock impedance (LVSI) is correlated with shock coil calcification. This trend is more prevalent with Boston Scientific’s RELIANCE ePTFE defibrillation leads compared to non-ePTFE defibrillation leads.

The FDA stated it is currently reviewing information about this potentially high-risk device issue and will keep the public informed as significant new information becomes available.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.